Antares pharma inc.

using Antares auto injector technology •~75% of all commercial lives covered • 18 Orange Book listed patents extending to 2038 •FY 2021 revenue of $62.2M, up 34% year-over-year XYOSTED® TLANDO™ •Oral testosterone replacement therapy (TRT) •Granted FDA approval on March 28, 2022 and commercially launched in June 2022 •2X/daily ...

Antares pharma inc. Things To Know About Antares pharma inc.

using Antares auto injector technology •~75% of all commercial lives covered • 18 Orange Book listed patents extending to 2038 •FY 2021 revenue of $62.2M, up 34% year-over-year XYOSTED® TLANDO™ •Oral testosterone replacement therapy (TRT) •Granted FDA approval on March 28, 2022 and commercially launched in June 2022 •2X/daily ...Oct 18, 2021 · Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced it has entered into an exclusive licensing agreement with Antares Pharma, Inc. to commercialize TLANDO in the United States. TLANDO is an oral testosterone product for testosterone replacement therapy ("TRT") in ... Track Antares Pharma Inc (ATRS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsJan 18, 2022 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ... May 19, 2022 ... Acquisition | ANTARES PHARMA INC | 25th May 2022 · ANTARES PHARMA INC will be removed from the Index. · The weight of ANTARES PHARMA INC (ATRS.

Dec 2, 2023 · Antares Pharma, Inc. (NASDAQ:ATRS) issued its quarterly earnings data on Thursday, November, 4th. The specialty pharmaceutical company reported $0.03 EPS for the quarter, meeting the consensus estimate of $0.03. The specialty pharmaceutical company earned $48.19 million during the quarter, compared to the consensus estimate of $48.52 million. Antares Pharma, Inc. (Exact Name of Registrant Specified in Charter) Delaware (State or Other. Jurisdiction of. Incorporation) 1-32302 (Commission File. Number) 41-1350192 (I.R.S. Employer. Identification No.) 250 Phillips Blvd., Suite 290, Ewing, NJ . 08618 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area …

Antares Pharma, Inc. (ATRS) is an emerging, specialty pharmaceutical company that focuses on the development and commercialization of self-administered …

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (AMEX: AIS - News) today announced the appointment of Paul K. Wotton, Ph.D., as the Company’s President and Chief Executive Officer effective immediately. Dr. Wotton previously served as President and Chief Operating Officer. Concurrently, Jack E. Stover has resigned as both …EWING, N.J., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced …A suit was filed on Wednesday in the Southern District of New York by investor Shiva Stein against defendants Antares Pharma, Inc., as well as the company’s board of directors. The complaint for ...Delaware . 1-32302 . 41-1350192 (State or Other Jurisdiction. of Incorporation) (Commission. File Number) (I.R.S. Employer. Identification No.) 100 Princeton South ...Apr 26, 2022 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in ...

SEC Filings. Next. Showing 1 to 50 of 619. Date. Title. Type. 2023-02-10. SC 13G/A [Amend] - Statement of acquisition of be. SC 13G/A.

May 6, 2021 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in ...

Antares Pharma, Inc. (NASDAQ: ATRS)’s sale to Halozyme Therapeutics, Inc. for $5.60 per share in cash. If you are an Antares Pharma shareholder, ...Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas.Antares Pharma, Inc. (“Antares,” “we,” “our,” “us” or the “Company”) is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas.Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself …Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...Antares Pharma, Inc. (Amex:AIS) has elected Leonard S. Jacob, M.D., Ph.D. to the Company ' s Board of Directors.. Dr. Leonard Jacob joins Antares with over 29 years of pharmaceutical industry experience including having founded InKine Pharmaceutical Company Inc. in 1997 and served as Chairman and CEO from its …

EWING, NJ, January 11, 2021 – Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced guidance for full-year 2021 and expects revenue to be in a range of $175 to $200 million, which assumes no significant disruptions to supply or operations due to the ongoing COVID-19 pandemic. Mar 3, 2022 · EWING, NJ, March 3, 2022 – Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today reported financial and operating results for the fourth quarter ended December 31, 2021 with record revenue of $48.7 million, net income of $32.7 million, or $0.19 per diluted earnings per share, and adjusted net income of $4.1 million, or $0.02 per adjusted diluted ... Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...May 24, 2022 · 24 May, 2022, 08:30 ET. SAN DIEGO, May 24, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (" Halozyme ") today announced the successful completion of its acquisition of Antares ... Antares Pharma is a leading company in the development and commercialization of self-administered injectable products. Learn more about its innovative portfolio, pipeline and financial performance in this investor presentation from January 2022. Sep 9, 2016 · Get the latest Antares Pharma Inc. (ATRS) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.

Antares Pharma Drug Portfolio. Antares Pharma focuses on the development and commercialization of self-administered pharmaceutical products and the technologies to deliver them. We have multiple internal product development programs, as well as partnerships with industry-leading pharmaceutical companies. Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...

Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...As previously disclosed, on February 28, 2014, Antares Pharma, Inc. (“Antares”) sued Medac Pharma, Inc. (“Medac”) and its foreign parent, medac GmbH, in the United States District Court for the District of Delaware alleging infringement. Antares is asserting four patents. On March 14, 2014, Antares filed a motion for preliminary injunction seeking to …As of April 22, 2022, there were 14,804,581 options to purchase shares of Company common stock (the “Company Options”), 1,606,322 restricted stock units of the Company (the “Company RSUs”) and 815,743 performance stock units of the Company (the “Company PSUs”) outstanding under the Antares Pharma, Inc. Equity Compensation Plan (the ...Antares Pharma announces FDA approval of Tlando™, an oral treatment for testosterone replacement therapy. News release. Antares Pharma Inc. Accessed March 29, 2022.Live Chat Inc. is a tool you can use to interact with customers or clients on the internet. More and more, consumers are demanding and expecting immediate help from the companies they approach. This application enables you to engage with cu...Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself or with partners, therapeutic …Scientific Publications. Curtis JR, Xie F, Zhang J, Chen L, Yun H, Beukelman T T, Ginsberg S, Schiff MH. “Patterns of Oral and Subcutaneous Methotrexate Use among Rheumatoid Arthritis Patients Enrolled in the U.S. Medicare Program. “ Poster presented at: The American College of Rheumatology, November 14-19, 2014: Boston, Ma.

Oct 1, 2018 · Antares Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery ...

Antares Pharma, Inc. (“Antares,” “we,” “our,” “us” or the “Company”) is an emerging, specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies.

Minnetonka, Minnesota (763) 475-7700 12500 Whitewater Drive Minnetonka, MN 55343 USAMay 24, 2022 · 24 May, 2022, 08:30 ET. SAN DIEGO, May 24, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (" Halozyme ") today announced the successful completion of its acquisition of Antares ... May 6, 2021 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in ... Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in ...He concurrently serves as the Director of the Board of Swiss based subsidiaries of the US pharmaceutical company Antares Pharma Inc. (Nasdaq: ATRS). Further to these noteworthy contributions, he ...Oct 1, 2018 · Antares Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery ... Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in ...Halozyme Therapeutics Inc (NASDAQ: HALO) will acquire Antares Pharma Inc (NASDAQ: ATRS) for $5.60 per share, valuing Antares at approximately 0 million. The transaction is expected to be accretive ...

SAN DIEGO and EWING, N.J., April 13, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") and Antares Pharma, Inc. …18. 10. 2021 ... Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered ...Oct 1, 2018 · Antares Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery ... Instagram:https://instagram. what dental insurance covers dentureswhat was the jobs report todayspectrum stocksspy stocks list Antares Pharma, Inc. is a combination drug device company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto ... du pont stockark next generation internet etf Antares Pharma Inc. Temple University - Fox School of Business and Management Report this profile About A senior pharmaceutical executive with over 20 years experience in operations, finance ... penny stock account Antares Pharma, Inc. (“Antares,” “we,” “our,” “us” or the “Company”) is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas.Antares Pharma, Inc. 2020 Q3 - Results - Earnings Call Presentation SA Transcripts Thu, Nov. 05, 2020 Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q3 2020 Results - Earnings Call TranscriptAntares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in ...